Adona Medical

Adona Medical is a Los Gatos, California-based clinical-stage medical device company developing adjustable interatrial shunting systems with integrated sensors for patients with advanced heart failure. The pre-commercial enterprise engineers implants that can be resized post-procedure using a proprietary induction catheter while capturing daily bi-atrial pressure readings without patient interaction. Currently operating with 34 employees, the pre-revenue firm has secured $92.5 million in total funding to advance its cardiovascular interventions, including a recent $33.5 million Series C financing round. Led by Cormorant Asset Management with participation from TCP Health Ventures and the Shifamed incubator, this capital follows the successful first-in-human use of its proprietary shunt and pressure monitoring system. Founded in 2019 as a Shifamed portfolio company, the organization was established by co-founders Brian Fahey, Amr Salahieh, and Lewis Schwartz to improve heart failure outcomes through device-based interventions.

High-Level Overview

Adona Medical is a clinical-stage medical technology company developing a novel interatrial shunt with integrated bi-atrial pressure monitoring for patients with advanced heart failure.[1][2][3][5] The device features an adjustable flow channel that can be resized post-implantation using a proprietary induction catheter, alongside sensors capturing multiple daily pressure readings from both atria without patient interaction, enabling more personalized therapy.[1][2][3][5] It serves heart failure patients and physicians seeking individualized management beyond fixed-geometry shunts, addressing limitations in applicability and adoption of first-generation devices.[1][2] The company, a Shifamed portfolio firm based in Los Gatos, California, has raised $92.5M total funding, including a $33.5M Series C in July 2024 to advance product development and early clinical use, and completed enrollment in its first-in-human ATHENS-HF study in June 2025 with 100% procedural success in 10 patients.[1][3][4]

Origin Story

Adona Medical emerged as a Shifamed portfolio company, with Brian Fahey as Co-Founder and CEO, leveraging Shifamed's medical innovation hub to develop advanced heart failure solutions.[1][3] The idea stemmed from gaps in existing therapies, focusing on interatrial shunting with remote monitoring to enable post-implantation adjustments and proactive management.[1][2] Early traction included showcasing the platform at CSI Frankfurt 2023 and securing Series C funding led by Cormorant Asset Management in July 2024.[1][4] A pivotal moment came in June 2025 with completion of enrollment in the ATHENS-HF first-in-human study ahead of schedule, implanting the device in 10 patients and demonstrating strong early results.[3]

Core Differentiators

• Adjustable Shunt Geometry: Unlike fixed-flow shunts, the flow channel can be enlarged or reduced post-implantation via induction catheter, allowing individualized treatment as patient conditions evolve.[1][2][3][5]
• Integrated Bi-Atrial Sensors: Captures direct left atrial (LA) and right atrial (RA) pressure readings 5+ times daily without patient input, providing physicians with comprehensive hemodynamic data for informed decisions.[1][2][3][5]
• Combined Therapeutic/Diagnostic Platform: Merges shunting with remote monitoring in one implant, aiming to transform heart failure management through proactive, data-driven adjustments.[3][5]
• Execution Momentum: Rapid progress from preclinical to clinical stage, with 100% procedural success in first-in-human trial and plans for next-generation devices.[3]

Role in the Broader Tech Landscape

Adona rides the wave of personalized cardiovascular interventions amid rising heart failure prevalence, where first-generation devices face adoption barriers due to one-size-fits-all designs.[1][2] Timing aligns with advances in implantable sensors and remote monitoring, fueled by market demand for tailored therapies—heart failure affects millions, yet current options limit applicability.[1] Favorable forces include investor confidence (e.g., Shifamed backing, Cormorant-led funding) and clinical momentum, positioning Adona to influence medtech by setting standards for adjustable, sensor-enabled implants.[1][3] It contributes to the ecosystem by advancing Shifamed's portfolio in hemodynamic solutions, potentially disrupting fixed-shunt markets through superior patient outcomes and physician tools.[2][3]

Quick Take & Future Outlook

Adona is poised to initiate evaluation of next-generation devices post-ATHENS-HF, expanding clinical programs and pursuing regulatory paths as an investigational device advances toward approval.[3] Trends like AI-augmented remote monitoring and precision medtech will shape its trajectory, amplifying data from bi-atrial sensors for predictive care. Its influence may grow by redefining heart failure standards, delivering the advanced solutions promised from inception and benefiting millions through Shifamed's innovation ecosystem.[1][3]